Clinical Trial Update: Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ipilimumab in combination with androgen suppression therapy for metastatic hormone-resistant prostate cancer has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Prostate
• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• androgen suppression therapy
• ipilimumab (ipilimumab)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-05-18